Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...

6 The Carney triad, caused by mutation of the SDH gene, is a rare, nonhereditary condition characterized by the presence of 3 different types of tumors: GISTs, pulmonary chondromas ... She has ...

Treatment with bezuclastinib plus Sutent led to safe and efficacious outcomes versus Sutent treatment alone in gastrointestinal stromal tumors.

[25] In view of these data, imatinib has become the first-line treatment for patients presenting with advanced GIST. Since the 800 mg dose causes more pronounced toxic effects but equivalent ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData, Phase II drugs for Gastrointestinal Stromal ...

The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...

In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...

The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.